Compare Sirius XM Holdings Inc (SIRI) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sirius XM Holdings Inc vs GeneDx Holdings Corp — how do they compare? Sirius XM Holdings Inc trades at $26.51 (market cap $8.87B), while GeneDx Holdings Corp trades at $67.33 (market cap $2.02B). The key difference: Sirius XM Holdings Inc is far larger — about 4.4× GeneDx Holdings Corp's market cap, and Sirius XM Holdings Inc pays a 4.1% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Sirius XM Holdings Inc for 102 Days and GeneDx Holdings Corp for 19 Days on average.
| SIRI | WGS | |
|---|---|---|
Market Cap | $8.87B | $2.02B |
Volume | 4,324,672 | 734,640 |
Sector | Media | Health |
52-Week High | $32.59 | $167.51 |
52-Week Low | $19.92 | $34.51 |
Typical Hold Time | 102 Days | 19 Days |
Enterprise Value | $18.16B | $2.05B |
Dividend Yield | 4.1% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sirius XM Holdings (SIRI) trades at $26.33, up 1.46% with mixed technical signals showing neutral momentum. The stock presents attractive valuation metrics with a P/E of 10.57 and P/B of 0.75, though recent earnings have been inconsistent with two misses in the last four quarters. Strong cash flow generation of $1.9B in 2025 supports the company's dividend payments and strategic initiatives, including recent YouTube advertising partnerships and technology leadership appointments.
SIRI offers value investment potential with upside to the $34.43 consensus price target, representing 31% potential return. However, investors face risks from inconsistent earnings performance and competitive pressures in the audio entertainment space. The company's improving balance sheet with debt-to-asset ratio declining to 35.63% provides financial stability, while institutional accumulation signals confidence in the turnaround story.
GeneDx (WGS) trades at $67.73, down 1.17% with bearish technical signals despite recent earnings beats. The company shows strong revenue growth to $454M in 2026 but faces profitability challenges with a -23.4% net margin. Recent developments include new genomic testing products and hospital partnerships, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth story with expanding genomic testing volumes but carries significant execution risk given negative profitability metrics. Upside potential exists if management can translate revenue growth into sustainable profits, though current cash flow trends and high valuation multiples warrant caution for risk-averse investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sirius XM Holdings Inc
SiriusXM Holdings is now composed of two businesses: SiriusXM and Pandora. SiriusXM transmits music, talk shows, sports, and news via its two satellite radio networks, primarily to consumers in vehicles who pay a subscription fee. The firm's radios come preinstalled on a wide range of light vehicles in the U.S. and Canada. The firm acquired Pandora Media in February 2019 via an all-stock transaction. Pandora is a streaming music platform that offers an ad-supported radio option and a paid on-demand service. Liberty Media owns 80% of SiriusXM, traded through its Liberty SiriusXM Group tracking stock.
Read more on SIRI →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
